Skip to main content
. 2012 May 17;106(12):1997–2003. doi: 10.1038/bjc.2012.145

Figure 1.

Figure 1

Association between JNK activation and poor therapeutic response to sorafenib in HCC. (A) Expression of phospho-c-Jun in HCC of patients with poor response (PD, n=18) and favourable response to sorafenib (PR, SD, n=17). Paraffin-embedded liver sections were immunostained with anti-phospho-c-Jun antibody. (B) Frequency of phospho-c-Jun-positive cells in HCCs. Data are the mean values±s.e. (C) Expression of phospho-JNK in HCC of patients with poor response (PD) and favourable response to sorafenib (PR, SD). Paraffin-embedded liver sections were immunostained with anti-phospho-JNK antibody.